The clinical investigation of Citrullus colocynthis (L.) Schrad. fruit in treatment of type II diabetic patients a randomized, double-blind, placebo-controlled study

Background and Aims: Citrullus colocynthis (Schrad) fruit is a toxic herbal medicine extensively used by traditional herbalists for the treatment of diabetes in several parts of Iran. Clinical investigation of its efficacy and its toxicity in diabetic patients is of importance.   Materials and Met...

Full description

Bibliographic Details
Main Authors: H Fallah Huseini, R Heshmat, B Larijani, H Fakhrzadeh, Z Jafariazar, F Darvishzadeh, M Rahmani, AH Shikh Samani
Format: Article
Language:English
Published: Institue of Medicinal Plants, ACECR 2006-03-01
Series:Journal of Medicinal Plants
Subjects:
Online Access:http://jmp.ir/article-1-599-en.html
id doaj-16dcbc110c97422bad2df4b0df341e06
record_format Article
spelling doaj-16dcbc110c97422bad2df4b0df341e062021-09-19T04:32:07ZengInstitue of Medicinal Plants, ACECRJournal of Medicinal Plants2717-204X2717-20582006-03-015173135The clinical investigation of Citrullus colocynthis (L.) Schrad. fruit in treatment of type II diabetic patients a randomized, double-blind, placebo-controlled studyH Fallah Huseini0R Heshmat1B Larijani2H Fakhrzadeh3Z Jafariazar4F Darvishzadeh5M Rahmani6AH Shikh Samani7 Institute of Medicinal Plants - ACECR 3- Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences. Tehran 2- Endocrinology & Metabolism Research Center, Tehran University of Medical Sciences Tehran 2- Endocrinology & Metabolism Research Center, Tehran University of Medical Sciences Tehran 4- Department of Pharmacognosy, Pharmacy College, Azad Univercity Tehran 2- Endocrinology & Metabolism Research Center, Tehran University of Medical Sciences Tehran 2- Endocrinology & Metabolism Research Center, Tehran University of Medical Sciences Tehran 5- Biochemistry, Ministry of health and Medical education Background and Aims: Citrullus colocynthis (Schrad) fruit is a toxic herbal medicine extensively used by traditional herbalists for the treatment of diabetes in several parts of Iran. Clinical investigation of its efficacy and its toxicity in diabetic patients is of importance.   Materials and Methods: A 2-month randomized double blind clinical trial was conducted in 50 type II diabetic patients in two matched groups. One group (n=25) received 100 mg Citrullus colocynthis capsule 3 times a day plus standard therapy, while the control group (n=25) received placebo plus standard therapy. The patients were visited monthly and glycosylated hemoglobin (HbA1c), fasting blood glucose, total cholesterol, LDL and HDL, triglyceride, SGOT, SGPT, ALK, BUN, serum creatinine levels were determined at the beginning and the end of the study after two months.   Results: There was significant decrease in HbA1c and fasting blood glucose level in citrullus colocynthis fruit treated patients after two months as compared to beginning of the treatment and also as compared to placebo group. Serum lipid level was not changed significantly. The liver enzyme level and creatinine level in blood was not changed significantly in citrullus colocynthis fruit treated patients. No serious side effect was observed except mild diarrhea in 10% of patients, that, subsided with continuation of treatment. Conclusion: The results showed that the Citrullus colocynthis fruit treatment with known gastrointestinal toxicity has beneficial effect as a complimentary therapy on improving glycemic profile in type II diabetic patients. The use of this herbal medicine in the dose of 300 mg in 3 divided doses showed no severe gasterointestinal symptom or liver and kidney abnormality during two months of therapy. The long term efficacy and toxicity of Citrullus colocynthis may be investigated in a large multi center clinical study.http://jmp.ir/article-1-599-en.htmlcitrullus colocynthisherbal medicinediabetesclinical trial
collection DOAJ
language English
format Article
sources DOAJ
author H Fallah Huseini
R Heshmat
B Larijani
H Fakhrzadeh
Z Jafariazar
F Darvishzadeh
M Rahmani
AH Shikh Samani
spellingShingle H Fallah Huseini
R Heshmat
B Larijani
H Fakhrzadeh
Z Jafariazar
F Darvishzadeh
M Rahmani
AH Shikh Samani
The clinical investigation of Citrullus colocynthis (L.) Schrad. fruit in treatment of type II diabetic patients a randomized, double-blind, placebo-controlled study
Journal of Medicinal Plants
citrullus colocynthis
herbal medicine
diabetes
clinical trial
author_facet H Fallah Huseini
R Heshmat
B Larijani
H Fakhrzadeh
Z Jafariazar
F Darvishzadeh
M Rahmani
AH Shikh Samani
author_sort H Fallah Huseini
title The clinical investigation of Citrullus colocynthis (L.) Schrad. fruit in treatment of type II diabetic patients a randomized, double-blind, placebo-controlled study
title_short The clinical investigation of Citrullus colocynthis (L.) Schrad. fruit in treatment of type II diabetic patients a randomized, double-blind, placebo-controlled study
title_full The clinical investigation of Citrullus colocynthis (L.) Schrad. fruit in treatment of type II diabetic patients a randomized, double-blind, placebo-controlled study
title_fullStr The clinical investigation of Citrullus colocynthis (L.) Schrad. fruit in treatment of type II diabetic patients a randomized, double-blind, placebo-controlled study
title_full_unstemmed The clinical investigation of Citrullus colocynthis (L.) Schrad. fruit in treatment of type II diabetic patients a randomized, double-blind, placebo-controlled study
title_sort clinical investigation of citrullus colocynthis (l.) schrad. fruit in treatment of type ii diabetic patients a randomized, double-blind, placebo-controlled study
publisher Institue of Medicinal Plants, ACECR
series Journal of Medicinal Plants
issn 2717-204X
2717-2058
publishDate 2006-03-01
description Background and Aims: Citrullus colocynthis (Schrad) fruit is a toxic herbal medicine extensively used by traditional herbalists for the treatment of diabetes in several parts of Iran. Clinical investigation of its efficacy and its toxicity in diabetic patients is of importance.   Materials and Methods: A 2-month randomized double blind clinical trial was conducted in 50 type II diabetic patients in two matched groups. One group (n=25) received 100 mg Citrullus colocynthis capsule 3 times a day plus standard therapy, while the control group (n=25) received placebo plus standard therapy. The patients were visited monthly and glycosylated hemoglobin (HbA1c), fasting blood glucose, total cholesterol, LDL and HDL, triglyceride, SGOT, SGPT, ALK, BUN, serum creatinine levels were determined at the beginning and the end of the study after two months.   Results: There was significant decrease in HbA1c and fasting blood glucose level in citrullus colocynthis fruit treated patients after two months as compared to beginning of the treatment and also as compared to placebo group. Serum lipid level was not changed significantly. The liver enzyme level and creatinine level in blood was not changed significantly in citrullus colocynthis fruit treated patients. No serious side effect was observed except mild diarrhea in 10% of patients, that, subsided with continuation of treatment. Conclusion: The results showed that the Citrullus colocynthis fruit treatment with known gastrointestinal toxicity has beneficial effect as a complimentary therapy on improving glycemic profile in type II diabetic patients. The use of this herbal medicine in the dose of 300 mg in 3 divided doses showed no severe gasterointestinal symptom or liver and kidney abnormality during two months of therapy. The long term efficacy and toxicity of Citrullus colocynthis may be investigated in a large multi center clinical study.
topic citrullus colocynthis
herbal medicine
diabetes
clinical trial
url http://jmp.ir/article-1-599-en.html
work_keys_str_mv AT hfallahhuseini theclinicalinvestigationofcitrulluscolocynthislschradfruitintreatmentoftypeiidiabeticpatientsarandomizeddoubleblindplacebocontrolledstudy
AT rheshmat theclinicalinvestigationofcitrulluscolocynthislschradfruitintreatmentoftypeiidiabeticpatientsarandomizeddoubleblindplacebocontrolledstudy
AT blarijani theclinicalinvestigationofcitrulluscolocynthislschradfruitintreatmentoftypeiidiabeticpatientsarandomizeddoubleblindplacebocontrolledstudy
AT hfakhrzadeh theclinicalinvestigationofcitrulluscolocynthislschradfruitintreatmentoftypeiidiabeticpatientsarandomizeddoubleblindplacebocontrolledstudy
AT zjafariazar theclinicalinvestigationofcitrulluscolocynthislschradfruitintreatmentoftypeiidiabeticpatientsarandomizeddoubleblindplacebocontrolledstudy
AT fdarvishzadeh theclinicalinvestigationofcitrulluscolocynthislschradfruitintreatmentoftypeiidiabeticpatientsarandomizeddoubleblindplacebocontrolledstudy
AT mrahmani theclinicalinvestigationofcitrulluscolocynthislschradfruitintreatmentoftypeiidiabeticpatientsarandomizeddoubleblindplacebocontrolledstudy
AT ahshikhsamani theclinicalinvestigationofcitrulluscolocynthislschradfruitintreatmentoftypeiidiabeticpatientsarandomizeddoubleblindplacebocontrolledstudy
AT hfallahhuseini clinicalinvestigationofcitrulluscolocynthislschradfruitintreatmentoftypeiidiabeticpatientsarandomizeddoubleblindplacebocontrolledstudy
AT rheshmat clinicalinvestigationofcitrulluscolocynthislschradfruitintreatmentoftypeiidiabeticpatientsarandomizeddoubleblindplacebocontrolledstudy
AT blarijani clinicalinvestigationofcitrulluscolocynthislschradfruitintreatmentoftypeiidiabeticpatientsarandomizeddoubleblindplacebocontrolledstudy
AT hfakhrzadeh clinicalinvestigationofcitrulluscolocynthislschradfruitintreatmentoftypeiidiabeticpatientsarandomizeddoubleblindplacebocontrolledstudy
AT zjafariazar clinicalinvestigationofcitrulluscolocynthislschradfruitintreatmentoftypeiidiabeticpatientsarandomizeddoubleblindplacebocontrolledstudy
AT fdarvishzadeh clinicalinvestigationofcitrulluscolocynthislschradfruitintreatmentoftypeiidiabeticpatientsarandomizeddoubleblindplacebocontrolledstudy
AT mrahmani clinicalinvestigationofcitrulluscolocynthislschradfruitintreatmentoftypeiidiabeticpatientsarandomizeddoubleblindplacebocontrolledstudy
AT ahshikhsamani clinicalinvestigationofcitrulluscolocynthislschradfruitintreatmentoftypeiidiabeticpatientsarandomizeddoubleblindplacebocontrolledstudy
_version_ 1717376450437316608